hydroxychloroquine - versus standard of care - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.00 [0.06, 16.44]< 10%2 studies (2/-)50.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.51 [0.07, 3.68]< 10%1 study (1/-)74.6 %NAnot evaluable important-
hospitalization 0.79 [0.34, 1.81]< 10%2 studies (2/-)71.3 %some concernnot evaluable moderateimportant-

safety endpoints 00

adverse events 178.20 [73.71, 430.85]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.